A review of carvedilol arrhythmia data in clinical trials

作者：Kowey PR^*

来源：Journal of Cardiovascular Pharmacology and Therapeutics, 2005, 10: S59-S68.

DOI：10.1177/10742484050100i407

• beta-blockers
• atrial fibrillation
• antiarrhythmics
• carvedilol

beta-Blockers are currently being evaluated more intensively to define their role in clinical use as antiarrhythinic agents. beta-Adrenergic blockade has been Studied in relation to atrial fibrillation, ventricular arrhythinias, and sudden death; however, it is apparent from a number of studies that not all beta-blockers are equally effective. Randomized clinical trial data, both in heart failure and post-myocardial infarction (MI) patients, have shown differences in mortality benefits in addition to a variable effect oil arrhythmias and sudden death. Carvedilol, a third-generation beta-blocker with proven clinical benefit in the management of heart failure and post-MI patients, has properties that may make it an effective antiarrhythmic agent. This paper reviews the current clinical arrhythmia data available for carvedilol front large-scale clinical trials and small studies. The trial evidence demonstrates that carvedilol therapy can be an effective adjunctive rate-control therapy in patients with atrial fibrillation, prevent mortality in patients with heart failure or post-MI with left ventricular dysfunction, with or without atrial fibrillation, and reduce its onset and the incidence of ventricular arrhythmia and sudden death.

• 出版日期2005-6